지원사업
학술연구/단체지원/교육 등 연구자 활동을 지속하도록 DBpia가 지원하고 있어요.
커뮤니티
연구자들이 자신의 연구와 전문성을 널리 알리고, 새로운 협력의 기회를 만들 수 있는 네트워킹 공간이에요.
논문 기본 정보
- 자료유형
- 학술저널
- 저자정보
- 발행연도
- 2017.7
- 수록면
- 678 - 687 (10page)
이용수
초록· 키워드
오류제보하기
Purpose We evaluated the clinical utility of excision repair cross-complementation group 1 (ERCC1) expression as a predictive biomarker for platinum-based chemotherapy in advanced nonsmall cell lung cancer (NSCLC).
Materials and Methods Eligible patients were randomly assigned to the GP (gemcitabine 1,250 mg/m2 on days 1 and 8, and cisplatin 75 mg/m2 on day 1 every 3 weeks) or IP (irinotecan 65 mg/m2 and cisplatin 30 mg/m2 on days 1 and 8 every 3 weeks) arm. The primary goal of this study was to compare the response rate (RR) of the GP and IP arms according to the ERCC1 expression level.
Results A total of 279 patients were randomly assigned to the GP (n=139) and IP (n=140) arms, among which 63% were ERCC1-positive and 268 patients were assessable for the RR. The GP and IP arms did not differ significantly with respect to the RR (29.8% vs. 27.0%, respectively; p=0.082), median progression-free survival (PFS; 4.5 months vs. 3.9 months, respectively; p=0.117), and overall survival (OS; 16.5 months vs. 16.7 months, respectively; p=0.313). When comparing the efficacy between the ERCC1-positive and ERCC1-negative groups, there was no significant difference in the RR (GP, 28.2% vs. 32.6%, respectively, p=0.509; IP, 30.2% vs. 21.6%, respectively, p=0.536), median PFS (GP, 4.6 months vs. 5.0 months, respectively, p=0.506; IP, 3.9 months vs. 3.7 months, respectively, p=0.748), or median OS (GP, 18.6 months vs. 11.9 months, respectively, p=0.070; IP, 17.5 months vs.
14.0 months, respectively, p=0.821).
Conclusion Immunohistochemical analysis of the ERCC1 expression level did not differentiate the efficacy of platinum-based chemotherapy in advanced NSCLC.
목차
등록된 정보가 없습니다.
참고문헌 (25)
참고문헌 신청
Cufer T / 2013 / Systemic therapy of advanced non-small cell lung cancer : major-developments of the last 5-years / Eur J Cancer 49:1216~1225
Cooper WA / 2011 / What's new in non-small cell lung cancer for pathologists : the importance of accurate subtyping, EGFR mutations and ALK rearrangements / Pathology 43:103~115
Schiller JH / 2002 / Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer / N Engl J Med 346:92~98
Ohe Y / 2007 / Randomized phase III study of cisplatin plus irinotecan versus carboplatin plus paclitaxel, cisplatin plus gemcitabine, and cisplatin plus vinorelbine for advanced non-small-cell lung cancer : Four-Arm Cooperative Study in Japan / Ann Oncol 18:317~323
Rose MC / 2014 / Pharmacogenomics of cisplatin sensitivity in non-small cell lung cancer / Genomics Proteomics Bioinformatics 12:198~209
Cooper WA / 2011 / What's new in non-small cell lung cancer for pathologists : the importance of accurate subtyping, EGFR mutations and ALK rearrangements / Pathology 43:103~115
Schiller JH / 2002 / Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer / N Engl J Med 346:92~98
Ohe Y / 2007 / Randomized phase III study of cisplatin plus irinotecan versus carboplatin plus paclitaxel, cisplatin plus gemcitabine, and cisplatin plus vinorelbine for advanced non-small-cell lung cancer : Four-Arm Cooperative Study in Japan / Ann Oncol 18:317~323
Rose MC / 2014 / Pharmacogenomics of cisplatin sensitivity in non-small cell lung cancer / Genomics Proteomics Bioinformatics 12:198~209
함께 읽어보면 좋을 논문
논문 유사도에 따라 DBpia 가 추천하는 논문입니다. 함께 보면 좋을 연관 논문을 확인해보세요!
-
ERCC1 Expression Can Predict Response to Platinum-Based Induction Chemotherapy in Head and Neck Cancer Cases
Asian Pacific journal of cancer prevention : APJCP
2016 .01
-
Investigating the Frequency of the ERCC1 Gene C8092A Polymorphism in Iranian Patients with Advanced Gastric Cancer
Asian Pacific journal of cancer prevention : APJCP
2016 .01
-
Genetic Association between ERCC5 rs17655 Polymorphism and Colorectal Cancer Risk: Evidence Based on a Meta-analysis
Asian Pacific journal of cancer prevention : APJCP
2015 .01
-
Nucleotide Excision Repair Gene ERCC2 and ERCC5 Variants Increase Risk of Uterine Cervical Cancer
Cancer Research and Treatment
2016 .01
-
Randomized Phase III Trial of Irinotecan Plus Cisplatin versus Etoposide Plus Cisplatin in Chemotherapy-Naïve Korean Patients with Extensive-Disease Small Cell Lung Cancer
Cancer Research and Treatment
2019 .01
-
Modification effect of PARP4 and ERCC1 gene polymorphisms on the relationship between particulate matter exposure and insulin resistance
환경독성보건학회 심포지엄 및 학술대회
2022 .05
-
PM2.5와 인슐린저항성 지표간의 관계에 있어서 복구유전자다형성의 영향
환경독성보건학회 심포지엄 및 학술대회
2017 .10
-
The Efficacy and Safety of Platinum/Vinorelbine as More Than Second-Line Chemotherapy for Advanced Non-small Cell Lung Cancer
Cancer Research and Treatment
2015 .01
-
Expression of TS, RRM1, ERCC1, TUBB3 and STMN1 Genes in Tissues of Non-small Cell Lung Cancer and its Significance in Guiding Postoperative Adjuvant Chemotherapy
Asian Pacific journal of cancer prevention : APJCP
2015 .01
-
Lung Cancer in Women, a Different Disease: Survival Differences by Sex in Turkey
Asian Pacific journal of cancer prevention : APJCP
2015 .01
-
Comparison of the Efficacy between Gemcitabine-Cisplatin and Capecitabine-Cisplatin Combination Chemotherapy for Advanced Biliary Tract Cancer
Cancer Research and Treatment
2015 .01
-
Metformin Addition to Chemotherapy in Stage IV Non-Small Cell Lung Cancer: an Open Label Randomized Controlled Study
Asian Pacific journal of cancer prevention : APJCP
2015 .01
-
Incorporating Erlotinib or Irinotecan Plus Cisplatin into Chemoradiotherapy for Stage III Non-small Cell Lung Cancer According to EGFR Mutation Status
Cancer Research and Treatment
2017 .01
-
Clinical Application of Recombinant Human Endostatin in Postoperative Early Complementary Therapy on Patients with Non-small Cell Lung Cancer in Chinese Mainland
Asian Pacific journal of cancer prevention : APJCP
2015 .01
-
Randomized Phase II Study of Pemetrexed Versus Gefitinib in Previously Treated Patients with Advanced Non-small Cell Lung Cancer
Cancer Research and Treatment
2016 .01
-
Multicenter Retrospective Analysis of Intraperitoneal Paclitaxel and Systemic Chemotherapy for Advanced Gastric Cancer with Peritoneal Metastasis
Journal of Gastric Cancer
2020 .01
-
Randomized Phase II Study of Afatinib Plus Simvastatin Versus Afatinib Alone in Previously Treated Patients with Advanced Nonadenocarcinomatous Non-small Cell Lung Cancer
Cancer Research and Treatment
2017 .01
-
Estimating the Survival of Patients With Lung Cancer: What Is the Best Statistical Model?
예방의학회지
2019 .01
-
Systemic Treatments for Metastatic Renal Cell Carcinoma: 10-Year Experience of Immunotherapy and Targeted Therapy
Cancer Research and Treatment
2016 .01
이 논문의 저자 정보
최근 본 자료
댓글(0)
0